|
Gene: CD2BP2 |
Gene summary for CD2BP2 |
Gene summary. |
Gene information | Species | Human | Gene symbol | CD2BP2 | Gene ID | 10421 |
Gene name | CD2 cytoplasmic tail binding protein 2 | |
Gene Alias | FWP010 | |
Cytomap | 16p11.2 | |
Gene Type | protein-coding | GO ID | GO:0000244 | UniProtAcc | A0A024QZC1 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
10421 | CD2BP2 | LZE4T | Human | Esophagus | ESCC | 5.02e-13 | 3.50e-01 | 0.0811 |
10421 | CD2BP2 | LZE7T | Human | Esophagus | ESCC | 6.15e-07 | 4.41e-01 | 0.0667 |
10421 | CD2BP2 | LZE8T | Human | Esophagus | ESCC | 4.14e-10 | 3.33e-01 | 0.067 |
10421 | CD2BP2 | LZE20T | Human | Esophagus | ESCC | 3.44e-06 | 1.77e-01 | 0.0662 |
10421 | CD2BP2 | LZE22T | Human | Esophagus | ESCC | 6.58e-11 | 5.93e-01 | 0.068 |
10421 | CD2BP2 | LZE24T | Human | Esophagus | ESCC | 4.34e-33 | 8.31e-01 | 0.0596 |
10421 | CD2BP2 | LZE6T | Human | Esophagus | ESCC | 6.90e-09 | 3.52e-01 | 0.0845 |
10421 | CD2BP2 | P1T-E | Human | Esophagus | ESCC | 1.33e-09 | 5.32e-01 | 0.0875 |
10421 | CD2BP2 | P2T-E | Human | Esophagus | ESCC | 3.52e-24 | 4.89e-01 | 0.1177 |
10421 | CD2BP2 | P4T-E | Human | Esophagus | ESCC | 3.73e-24 | 6.43e-01 | 0.1323 |
10421 | CD2BP2 | P5T-E | Human | Esophagus | ESCC | 4.96e-24 | 4.82e-01 | 0.1327 |
10421 | CD2BP2 | P8T-E | Human | Esophagus | ESCC | 4.00e-33 | 4.30e-01 | 0.0889 |
10421 | CD2BP2 | P9T-E | Human | Esophagus | ESCC | 5.66e-15 | 2.15e-01 | 0.1131 |
10421 | CD2BP2 | P10T-E | Human | Esophagus | ESCC | 3.45e-29 | 3.84e-01 | 0.116 |
10421 | CD2BP2 | P11T-E | Human | Esophagus | ESCC | 2.00e-17 | 6.03e-01 | 0.1426 |
10421 | CD2BP2 | P12T-E | Human | Esophagus | ESCC | 4.46e-35 | 8.08e-01 | 0.1122 |
10421 | CD2BP2 | P15T-E | Human | Esophagus | ESCC | 6.41e-32 | 5.25e-01 | 0.1149 |
10421 | CD2BP2 | P16T-E | Human | Esophagus | ESCC | 4.48e-23 | 4.17e-01 | 0.1153 |
10421 | CD2BP2 | P17T-E | Human | Esophagus | ESCC | 2.36e-04 | 4.08e-01 | 0.1278 |
10421 | CD2BP2 | P19T-E | Human | Esophagus | ESCC | 8.69e-14 | 6.48e-01 | 0.1662 |
Page: 1 2 3 4 5 6 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Cervix | N_HPV | |
Endometrium | AEH | |
Endometrium | EEC | |
Prostate | BPH | |
Prostate | Tumor |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0022613111 | Esophagus | ESCC | ribonucleoprotein complex biogenesis | 365/8552 | 463/18723 | 1.74e-49 | 1.11e-45 | 365 |
GO:0008380111 | Esophagus | ESCC | RNA splicing | 336/8552 | 434/18723 | 1.74e-42 | 3.67e-39 | 336 |
GO:0000375111 | Esophagus | ESCC | RNA splicing, via transesterification reactions | 248/8552 | 324/18723 | 3.05e-30 | 1.49e-27 | 248 |
GO:0000377111 | Esophagus | ESCC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 244/8552 | 320/18723 | 2.52e-29 | 1.07e-26 | 244 |
GO:0000398111 | Esophagus | ESCC | mRNA splicing, via spliceosome | 244/8552 | 320/18723 | 2.52e-29 | 1.07e-26 | 244 |
GO:0071826111 | Esophagus | ESCC | ribonucleoprotein complex subunit organization | 166/8552 | 227/18723 | 2.94e-17 | 2.42e-15 | 166 |
GO:0022618111 | Esophagus | ESCC | ribonucleoprotein complex assembly | 159/8552 | 220/18723 | 8.19e-16 | 5.71e-14 | 159 |
GO:00003875 | Esophagus | ESCC | spliceosomal snRNP assembly | 32/8552 | 50/18723 | 6.90e-03 | 2.52e-02 | 32 |
GO:000838012 | Liver | Cirrhotic | RNA splicing | 229/4634 | 434/18723 | 9.13e-37 | 2.86e-33 | 229 |
GO:002261312 | Liver | Cirrhotic | ribonucleoprotein complex biogenesis | 231/4634 | 463/18723 | 3.28e-32 | 6.86e-29 | 231 |
GO:000037512 | Liver | Cirrhotic | RNA splicing, via transesterification reactions | 175/4634 | 324/18723 | 5.95e-30 | 7.47e-27 | 175 |
GO:000037712 | Liver | Cirrhotic | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 172/4634 | 320/18723 | 4.02e-29 | 3.60e-26 | 172 |
GO:000039812 | Liver | Cirrhotic | mRNA splicing, via spliceosome | 172/4634 | 320/18723 | 4.02e-29 | 3.60e-26 | 172 |
GO:007182612 | Liver | Cirrhotic | ribonucleoprotein complex subunit organization | 115/4634 | 227/18723 | 2.67e-17 | 3.63e-15 | 115 |
GO:002261812 | Liver | Cirrhotic | ribonucleoprotein complex assembly | 112/4634 | 220/18723 | 4.35e-17 | 5.81e-15 | 112 |
GO:002261322 | Liver | HCC | ribonucleoprotein complex biogenesis | 355/7958 | 463/18723 | 7.76e-52 | 4.92e-48 | 355 |
GO:000838022 | Liver | HCC | RNA splicing | 313/7958 | 434/18723 | 1.36e-36 | 1.73e-33 | 313 |
GO:000037522 | Liver | HCC | RNA splicing, via transesterification reactions | 228/7958 | 324/18723 | 1.47e-24 | 4.06e-22 | 228 |
GO:000037722 | Liver | HCC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 224/7958 | 320/18723 | 1.16e-23 | 2.62e-21 | 224 |
GO:000039822 | Liver | HCC | mRNA splicing, via spliceosome | 224/7958 | 320/18723 | 1.16e-23 | 2.62e-21 | 224 |
Page: 1 2 3 4 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CD2BP2 | SNV | Missense_Mutation | c.871G>T | p.Gly291Trp | p.G291W | O95400 | protein_coding | deleterious(0.02) | possibly_damaging(0.52) | TCGA-C8-A12O-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
CD2BP2 | SNV | Missense_Mutation | rs777916992 | c.456N>A | p.Met152Ile | p.M152I | O95400 | protein_coding | tolerated(0.14) | benign(0) | TCGA-C5-A7UH-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
CD2BP2 | SNV | Missense_Mutation | c.1007N>C | p.Asp336Ala | p.D336A | O95400 | protein_coding | deleterious(0.01) | probably_damaging(0.927) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | |
CD2BP2 | SNV | Missense_Mutation | c.8N>C | p.Lys3Thr | p.K3T | O95400 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AA-3875-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
CD2BP2 | SNV | Missense_Mutation | c.308N>A | p.Ala103Asp | p.A103D | O95400 | protein_coding | deleterious(0.03) | benign(0.039) | TCGA-AA-3952-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD | |
CD2BP2 | SNV | Missense_Mutation | rs779646330 | c.119N>A | p.Arg40His | p.R40H | O95400 | protein_coding | deleterious(0.01) | probably_damaging(0.968) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
CD2BP2 | SNV | Missense_Mutation | c.136T>A | p.Ser46Thr | p.S46T | O95400 | protein_coding | tolerated(0.09) | probably_damaging(0.996) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
CD2BP2 | SNV | Missense_Mutation | rs751813994 | c.159N>T | p.Glu53Asp | p.E53D | O95400 | protein_coding | tolerated(1) | probably_damaging(0.994) | TCGA-D5-6927-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
CD2BP2 | deletion | Frame_Shift_Del | c.177delG | p.Ser60ProfsTer12 | p.S60Pfs*12 | O95400 | protein_coding | TCGA-NH-A5IV-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |||
CD2BP2 | deletion | Frame_Shift_Del | c.177delG | p.Ser60ProfsTer12 | p.S60Pfs*12 | O95400 | protein_coding | TCGA-WS-AB45-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |